Roche Holding AG’s lung cancer drug scored a big win against a standard therapy in a study this week. Now, the Swiss drugmaker is turning to artificial intelligence to find patients who can benefit.
A panel of expert advisers to the US Food and Drug Administration will meet on Thursday to discuss whether a lung cancer therapy that has been studied only in China should be approved in the US, and whether trial results are applicable to the US population.
FDA OKs 1st targeted drug for common lung cancer mutation
LINDA A. JOHNSON, AP Medical Writer
May 28, 2021
FacebookTwitterEmail
This image provided by Amgen in May 2021 shows packaging for their medication Lumakras. On Friday, May 28, 2021, the U.S. Food and Drug Administration approved Lumakras, the first medicine for adults with advanced non-small cell lung cancer whose tumors have a common genetic mutation long considered untreatable with drugs. Each year, about 13,000 U.S. patients are diagnosed with this cancer and mutation. (Amgen via AP)AP
FAIRLESS HILLS, PA. (AP) U.S. regulators have approved the first medicine for patients with the most common type of lung cancer whose tumors have a genetic mutation long considered untreatable with drugs.